Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391880 | 0.80 | CA2 (0.34) | — | |
| SCHEMBL3393974 | 0.80 | CA2 (0.39) | — | |
| SCHEMBL3392911 | 0.77 | KDM4E (0.32) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3397609 | 0.77 | CA2 (0.31) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3396256 | 0.77 | KDM4E (0.31) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL8037350 | 0.74 | KDM4E (0.31) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL16993320 | 0.73 | ACHE (0.33) | — | |
| SCHEMBL233448 | 0.72 | KDM4E (0.36) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3389592 | 0.71 | CA2 (0.34) | — | |
| SCHEMBL58243 | 0.71 | CYP3A4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070111997-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-17 | — | — | US | disclosed |
| US-7138401-B2 | 2-aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| US-7129244-B2 | Triazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| US-20050113339-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113339-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | KDM4E 4038/4885ALDH1A1 2195/4885HSD17B10 2206/4885 |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | KDM4E 3577/4885ALDH1A1 827/4885HSD17B10 2018/4885 |
| US-20070111997-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | KDM4E 4038/4885ALDH1A1 2195/4885HSD17B10 2206/4885 |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | HSP90AB2P, HSP90AB1, HSP90AA1 | KDM4E 3577/4885ALDH1A1 827/4885HSD17B10 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.